Melanoma and Nevi: Detection and Diagnosis

Current Problems in Cancer

Volumn 35, Issue 4, 2011, Pages 138-161

  Choi, Jennifer Nam ^a   Hanlon, Allison ^a   Leffell, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; IMIQUIMOD; SUNSCREEN;

AGING; AMELANOTIC MELANOMA; ARTICLE; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CELL SPREADING; CONGENITAL NEVUS; DRUG EFFICACY; DYSPLASTIC NEVUS; FAMILY HISTORY; FIBROMA; HEREDITY; HUMAN; IMMUNE STATUS; MALIGNANT LENTIGO; MEDICAL HISTORY; MELANOCYTIC NEVUS; MELANOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SKIN BIOPSY; ULTRAVIOLET RADIATION;

AGE FACTORS; EARLY DIAGNOSIS; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MELANOMA; NEVUS; RISK FACTORS; SKIN NEOPLASMS;

EID: 80052655806     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2011.07.005     Document Type: Article

References (130)

1. Howlader N, NA, Krapcho M, et al. SEER Cancer Statistics Review:1975-2008. Bethesda, MD: National Cancer Institute, based on 2010 SEER data submission, posted to the SEER web site, 2011. 2011 SEER Cancer Statistics Review 1975-2008. Surveillance Epidemiology and End Results. http://seer.cancer.gov/csr/1975_2008/.
2. SEER Cancer Statistics Review, 1975-2007 2010, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site. S.F. Altekruse, C.L. Kosary, M. Krapcho (Eds.).
3. Bleyer A., OLM, Barr R., et al. National Cancer Institute. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000 2006, National Cancer Institute, Bethesda, MD.
4. Cancer Facts and Figures 2010 2010, American Cancer Society, American Cancer Society, Atlanta, GA.
5. Linos E., Swetter S.M., Cockburn M.G., et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129(7):1666-1674.
6. Eide M.J., Weinstock M.A. Association of UV index, latitude, and melanoma incidence in nonwhite populations-US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 2005, 141(4):477-481.
7. Westerdahl J., Måsbäck A., et al. Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity. Br J Cancer 2000, 82:1593-1599. IC.
8. Friedman R.J., Rigel D.S., Kopf A.W. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985, 35:130-151.
9. Gonzalez A., Pitha J.V., et al. Small diameter invasive melanoma: clinical and pathological characteristics. J Cutan Pathol 1996, 23:123-132. WA.
10. Abbasi N.R., Rigel D.S., et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004, 292(22):2771-2776. SH.
11. Grob J.J. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998, 134(1):103-104. BJ.
12. Piccolo D., Peris K., et al. Dermoscopic diagnosis by a trained clinician vs. a clinician with minimal dermoscopy training vs. computer-aided diagnosis of 341 pigmented skin lesions: a comparative study. Br J Dermatol 2002, 147:481-486. FA.
13. Withelier D.D. Sensitivity of diagnosis of malignant melanoma: a clinicopathologic study with a critical assessment of biopsy techniques. Exp Dermatol 1992, 4:170-175.
14. Zager J.S., Hochwald S.N., Marzban S.S., et al. Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg 2011, 212:454-460.
15. Markovic S.N., Erickson L.A., Rao R.D., et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007, 82:364-380.
16. Bradford P.T., Goldstein A.M., Tamura D., et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011, 48(3):168-176.
17. Chiarugi A., Crocetti E., Carli P., et al. Familial and sporadic melanoma: different clinical and histopathological features in the Italian population-a multicentre epidemiological study-by GIPMe. J Eur Acad Dermatol Venereol 2011, [epub ahead of print].
18. Mazumder A., Rosenberg S.A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984, 159(2):495-507.
19. Yuan J., Li H., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008, 105(51):20410-20415. GS.
20. Zwald F.O., Billingsley E.M., et al. Melanoma in solid organ transplant recipients. Am J Transplant 2010, 5:1297-1304. CL.
21. Eller M.S., Ostrum K., Gilchrest B.A. DNA damage enhances melanogenesis. Proc Natl Acad Sci USA 1996, 93(3):1087.
22. Scott M.C., Ito S., et al. Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci 2002, 115:2349-2355. WK.
23. Schmid-Wendtner M.H., Wendtner C.M., et al. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001, 145(6):981-985. BJ.
24. Bricca G.M., Ren D., et al. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005, 52:92-100. BD.
25. Bene N.I., Coldiron B.M. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg 2008, 34:660-664. HC.
26. Möller M.G., Zager J.S., Santiago L.A., et al. Surgical management of melanoma in situ using a staged marginal and central excision technique. Ann Surg Oncol 2009, 16:1526-1536.
27. Naylor M.F., Kuwahara R., et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003, 149(suppl 66):66-69. CN.
28. Fleming C.J., Bryden A.M., Evans A., et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004, 151:485-488.
29. Cotter M.A., Bowen G.M. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2007, 34:147-151. MJ.
30. Cornejo P., Polimon I., et al. Intralesional interferon treatment of lentigo maligna. Arch Dermatol 2000, 136:428-430. VF.
31. Madan V. Lentigo maligna-outcomes of treatment with Q-switched Nd:YAG and alexandrite lasers. Dermatol Surg 2009, 35:607-612. AP.
32. Skender-Kalnenas T.M., Heenan P.J. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?. J Am Acad Dermatol 1995, 33:1000-1007. ED.
33. Chang A.E., Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998, 83:1664-1678. KL.
34. Segura S., Puig S., et al. In vivo microscopic features of nodular melanomas: dermoscopy, confocal microscopy, and histopathologic correlates. Arch Dermatol 2008, 144:1311-1320. PG.
35. Bradford P.T., Goldstein A.M., McMaster M.L., et al. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 2009, 145(4):427-434.
36. Di Chiacchio N., Hirata S.H., Enokihara M.Y., et al. Dermatologists' accuracy in early diagnosis of melanoma of the nail matrix. Arch Dermatol 2010, 146(4):382-387.
37. Leyden J.J., Spott D.A., Goldschmidt H. Diffuse and banded melanin pigmentation in nails. Arch Dermatol 1972, 105:548-550.
38. Feng Z., Chen V., et al. Incidence and survival of desmoplastic melanoma in the United States, 1992-2007. J Cutan Pathol 2011, WX, [Epub ahead of print].
39. Davies H., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. BG.
40. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
41. Onken M.D., Long M.D., et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008, 49:5230-5234. WL.
42. Van Raamsdonk C.D., Crosby M.B., et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363:2191-2199. GK.
43. Valiukeviciene S., Miseviciene I., Gollnick H. The prevalence of common acquired melanocytic nevi and the relationship with skin type characteristics and sun exposure among children in Lithuania. Arch Dermatol 2005, 141(5):579-586.
44. Whiteman D.C., Brown R.M., Purdie D.M., et al. Melanocytic nevi in very young children: the role of phenotype, sun exposure, and sun protection. J Am Acad Dermatol 2005, 52(1):40-47.
45. LaVigne E.A., Oliveria S.A., Dusza S.W., et al. Clinical and dermoscopic changes in common melanocytic nevi in school children: the Framingham school nevus study. Dermatology 2005, 211(3):234-239.
46. Holly E.A., Kelly J.W., Shpall S.N., et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987, 17(3):459-468.
47. Grob J.J., Gouvernet J., Aymar D., et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990, 66(2):387-395.
48. Swerdlow A.J., English J., MacKie R.M., et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986, 292(6535):1555-1559.
49. Barnhill R.L., Rabinovitz H. Benign Melanocytic Neoplasms. Dermatology 2008, 1713-1740. Mosby-Elsevier, Spain. 2nd edition. J.L. Bolognia, J.L. Jorizzo, R.P. Rapini (Eds.).
50. Clark W.H., Reimer R.R., Greene M., et al. Origin of familial malignant melanomas from heritable melanocytic lesions. The BK Mole Syndr. Arch Dermatol 1978, 114(5):732-738.
51. Greene M.H., Clark W.H., Tucker M.A., et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980, 2(8202):1024.
52. Sagebiel R.W., Banda P.W., Schneider J.S., et al. Age distribution and histologic patterns of dysplastic nevi. J Am Acad Dermatol 1985, 13(6):975-982.
53. Elder D.E. The dysplastic nevus. Pathology 1985, 17(2):291-297.
54. Rhodes A.R., Mihm M.C., Weinstock M.A. Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol 1989, 2(4):306-319.
55. Roth M.E., Grant-Kels J.M., Ackerman A.B., et al. The histopathology of dysplastic nevi. Continued controversy. Am J Dermatopathol 1991, 13(1):38-51.
56. Seywright M.M., Doherty V.R., MacKie R.M. Proposed alternative terminology and subclassification of so called "dysplastic naevi". J Clin Pathol 1986, 39(2):189-194.
57. Ackerman A.B., Milde P. Naming acquired melanocytic nevi. Common and dysplastic, normal and atypical, or Unna, Miescher, Spitz, and Clark? Am J Dermatopathol 1992, 14(5):447-453.
58. Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma. Am J Dermatopathol 1993, 15(1):34-43. National Institutes of Health, [Discussion 46-51].
59. Friedman R.J., Farber M.J., Warycha M.A., et al. The "dysplastic" nevus. Clin Dermatol 2009, 27(1):103-115.
60. Shapiro M., Chren M.M., Levy R.M., et al. Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol 2004, 31(8):523-530.
61. Piepkorn M., Meyer L.J., Goldgar D., et al. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 1989, 20(3):407-415.
62. Elder D.E., Clark W.H., Elenitsas R., et al. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol 1993, 10(1):18-35.
63. Consensus conference: Precursors to malignant melanoma. JAMA 1984, 251(14):1864-1866. Consensus Conference.
64. Nordlund J.J., Kirkwood J., Forget B.M., et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985, 45(4):1855-1861.
65. Augustsson A., Stierner U., Rosdahl I., et al. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991, 71(6):518-524.
66. Garbe C., Büttner P., Weiss J., et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994, 102(5):695-699.
67. Tucker M.A., Halpern A., Holly E.A., et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997, 277(18):1439-1444.
68. Richard M.A., Grob J.J., Gouvernet J., et al. Role of sun exposure on nevus. First study in age-sex phenotype-controlled populations. Arch Dermatol 1993, 129(10):1280-1285.
69. Naeyaert J.M., Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003, 349(23):2233-2240.
70. Halpern A.C., Guerry D., Elder D.E., et al. Natural history of dysplastic nevi. J Am Acad Dermatol 1993, 29(1):51-57.
71. Clemente C., Cochran A.J., Elder D.E., et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol 1991, 22(4):313-319.
72. Halpern A.C., Guerry D., Elder D.E., et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991, 127(7):995-999.
73. Tucker M.A., Fraser M.C., Goldstein A.M., et al. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993, 100(3):350S-355S.
74. Carey W.P., Thompson C.J., Synnestvedt M., et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994, 74(12):3118-3125.
75. Rigel D.S., Rivers J.K., Kopf A.W., et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989, 63(2):386-389.
76. Kang S., Barnhill R.L., Mihm M.C., et al. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994, 130(8):999-1001.
77. Shors A.R., Kim S., White E., et al. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol 2006, 155(5):988-993.
78. Roush G.C., Nordlund J.J., Forget B., et al. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 1988, 17(3):273-279.
79. MacKie R.M., Aitchison T.C., Freudenberger T. Risk factors for melanoma. Lancet 1989, 2(8668):928.
80. Halpern A.C., Guerry D., Elder D.E., et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993, 100(3):346S-349S.
81. Elder D.E., Greene M.H., Bondi E.E., et al. Acquired melanocytic nevi and melanoma: the dysplastic nevus syndrome. Pathology of Malignant Melanoma 1981, 185-216. Masson, New York, NY. A.B. Ackerman (Ed.).
82. Banky J.P., Kelly J.W., English D.R., et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005, 141(8):998-1006.
83. Stolz W., Schmoeckel C., Landthaler M., et al. Association of early malignant melanoma with nevocytic nevi. Cancer 1989, 63(3):550-555.
84. Black W.C. Residual dysplastic and other nevi in superficial spreading melanoma. Clinical correlations and association with sun damage. Cancer 1988, 62(1):163-173.
85. Clark W.H., Elder D.E., Guerry D., et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984, 15(12):1147-1165.
86. Gruber S.B., Barnhill R.L., Stenn K.S., et al. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol 1989, 21(4 Pt 1):773-780.
87. Hastrup N., Osterlind A., Drzewiecki K.T., et al. The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas. Am J Dermatopathol 1991, 13(4):378-385.
88. Marks R., Dorevitch A.P., Mason G. Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990, 31(2):77-80.
89. Rhodes A.R., Harrist T.J., Day C.L., et al. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol 1983, 9(4):563-574.
90. Skender-Kalnenas T.M., English D.R., Heenan P.J. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?. J Am Acad Dermatol 1995, 33(6):1000-1007.
91. Bevona C., Goggins W., Quinn T., et al. Cutaneous melanomas associated with nevi. Arch Dermatol 2003, 139(12):1620-1624. [Discussion 1624].
92. Kumar R., Angelini S., Snellman E., et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004, 122(2):342-348.
93. Loewe R., Kittler H., Fischer G., et al. BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol 2004, 123(4):733-736.
94. Tsao H., Bevona C., Goggins W., et al. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003, 139(3):282-288.
95. Rivers J.K., Kopf A.W., Vinokur A.F., et al. Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi. Cancer 1990, 65(5):1232-1236.
96. Kelly J.W., Yeatman J.M., Regalia C., et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 1997, 167(4):191-194.
97. Rhodes A.R. Intervention strategy to prevent lethal cutaneous melanoma: use of dermatologic photography to aid surveillance of high-risk persons. J Am Acad Dermatol 1998, 39(2 Pt 1):262-267.
98. Elder D.E. Dysplastic naevi: an update. Histopathology 2010, 56(1):112-120.
99. de Wit P.E., van't Hof-Grootenboer B., Ruiter D.J., et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer 1993, 29A(6):831-839.
100. Duncan L.M., Berwick M., Bruijn J.A., et al. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993, 100(3):318S-321S.
101. Duray P.H., DerSimonian R., Barnhill R., et al. An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol 1992, 27(5 Pt 1):741-749.
102. Rabkin M.S. The limited specificity of histological examination in the diagnosis of dysplastic nevi. J Cutan Pathol 2008, 35(Suppl 2):20-23.
103. van Dijk M.C., Aben K.K., van Hees F., et al. Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesions. Histopathology 2008, 52(2):139-146.
104. Klein L.J., Barr R.J. Histologic atypia in clinically benign nevi. A prospective study. J Am Acad Dermatol 1990, 22(2 Pt 1):275-282.
105. Green A.C., Williams G.M., Logan V., et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011, 29(3):257-263.
106. Barnes L.M., Nordlund J.J. The natural history of dysplastic nevi. A case history illustrating their evolution. Arch Dermatol 1987, 123(8):1059-1061.
107. Walton R.G., Jacobs A.H., Cox A.J. Pigmented lesions in newborn infants. Br J Dermatol 1976, 95(4):389-396.
108. Alper J.C., Holmes L.B. The incidence and significance of birthmarks in a cohort of 4,641 newborns. Pediatr Dermatol 1983, 1(1):58-68.
109. Makkar H.S., Frieden I.J. Congenital melanocytic nevi: an update for the pediatrician. Curr Opin Pediatr 2002, 14(4):397-403.
110. Tromberg J., Bauer B., Benvenuto-Andrade C., et al. Congenital melanocytic nevi needing treatment. Dermatol Ther 2005, 18(2):136-150.
111. Schaffer J.V. Pigmented lesions in children: when to worry. Curr Opin Pediatr 2007, 19(4):430-440.
112. Castilla E.E., da Graça Dutra M., Orioli-Parreiras I.M. Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies. Br J Dermatol 1981, 104(3):307-315.
113. Ichii-Nakato N., Takata M., Takayanagi S., et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006, 126(9):2111-2118.
114. Bauer J., Curtin J.A., Pinkel D., et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007, 127(1):179-182.
115. Dessars B., De Raeve L.E., Morandini R., et al. Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol 2009, 129(1):139-147.
116. Ruiz-Maldonado R., Tamayo L., Laterza A.M., et al. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992, 120(6):906-911.
117. Price H.N., Schaffer J.V. Congenital melanocytic nevi-when to worry and how to treat: facts and controversies. Clin Dermatol 2010, 28(3):293-302.
118. Ka V.S., Dusza S.W., Halpern A.C., et al. The association between large congenital melanocytic naevi and cutaneous melanoma: preliminary findings from an Internet-based registry of 379 patients. Melanoma Res 2005, 15(1):61-67.
119. Sahin S., Levin L., Kopf A.W., et al. Risk of melanoma in medium-sized congenital melanocytic nevi: a follow-up study. J Am Acad Dermatol 1998, 39(3):428-433.
120. Swerdlow A.J., English J.S., Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995, 32(4):595-599.
121. Tannous Z.S., Mihm M.C., Sober A.J., et al. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005, 52(2):197-203.
122. Berg P., Lindelöf B. Congenital melanocytic naevi and cutaneous melanoma. Melanoma Res 2003, 13(5):441-445.
123. Bett B.J. Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. J Am Acad Dermatol 2005, 52(5):793-797.
124. Marghoob A.A. Congenital melanocytic nevi. Evaluation and management. Dermatol Clin 2002, 20(4):607-616. viii.
125. Egan C.L., Oliveria S.A., Elenitsas R., et al. Cutaneous melanoma risk and phenotypic changes in large congenital nevi: a follow-up study of 46 patients. J Am Acad Dermatol 1998, 39(6):923-932.
126. Kadonaga J.N., Frieden I.J. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol 1991, 24(5 Pt 1):747-755.
127. Hale E.K., Stein J., Ben-Porat L., et al. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi-results from the NYU-LCMN registry. Br J Dermatol 2005, 152(3):512-517.
128. Agero A.L., Benvenuto-Andrade C., Dusza S.W., et al. Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry. J Am Acad Dermatol 2005, 53(6):959-965.
129. Kinsler V.A., Chong W.K., Aylett S.E., et al. Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice. Br J Dermatol 2008, 159(4):907-914.
130. Dragieva G., Hafner J., Künzi W., et al. Malignant melanoma in a large congenital melanocytic nevus 9 years after dermabrasion in childhood. Dermatology 2006, 212(2):208-209.